On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

The most popular FierceBiotech stories of 2015

Why would Martin Shkreli hike an old drug price by 5,000%? Only a 'moron' would ask Back when Martin Shkreli was CEO of Retrophin, he managed to grab a few headlines by buying an old...

Exelixis wins EU nod for cancer combo; Merck KGaA, Pfizer pick up orphan designation;

@FierceBiotech: FierceBiotech Radio on the ins and outs of 'Pfizergan' and whatever it is Martin Shkreli's doing. More | Follow @FierceBiotech @JohnCFierce: Any journos who would like to...

Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products

DARMSTADT, Germany & NEW YORK--()--Merck KGaA, Darmstadt, Germany, and Pfizer today announced that the European Medicines Agency (EMA)'s Committee for Orphan Medicinal Products...

Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma

-- COTELLIC's third regulatory approval, following Switzerland (August 2015) and the United States (November 2015) -- -- Exelixis eligible to receive royalties on ex-U.S. sales, including EU,...

Novo Nordisk taps Ablynx in a $400M deal

Novo Nordisk signed a deal with Ablynx worth up to €377 million ($400 million) to collaborate on so-called nanobodies, antibody fragments designed to split the difference between biologics and small-molecule drugs.

Allergan scoops up some CNS drugs as its $160B Pfizer merger pends

Allergan, seeking to burnish its reputation in R&D, bought into some early-stage treatments for autism and obsessive-compulsive disorder as it prepares to join forces with Pfizer in a massive merger.

Allergan and Rugen Therapeutics Announce Collaboration to Discover and Develop Ground-Breaking Medicines to Treat Autism Spectrum Disorders and Obsessive-Compulsive Disorders

-- Reinforces Allergan's Commitment to Patients and to Open Science - Accessing External Innovation to Build a Strong CNS Pipeline -- -- Allergan and Rugen Have Identified and Will Advance...

Teva wagers up to $410M on Heptares' migraine program

Heptares Therapeutics, acquired by Japan's Sosei earlier this year, signed a deal with Teva Pharmaceutical to co-develop novel migraine treatments, getting in line for as much as $410 million.

Teva and Heptares Enter Agreement to Discover and Develop Novel, Small-Molecule CGRP Antagonists for Treatment of Migraine

Teva to receive worldwide development and commercial rights to novel CGRP antagonists Heptares to receive $10 million upfront with up to $400 million in potential milestone payments Jerusalem and...